Cara Therapeutics (CARA) Competitors $0.30 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CARA vs. BYSI, CLRB, ALVR, ALGS, CELU, ALXO, IMRX, MGX, SPRO, and INCRShould you be buying Cara Therapeutics stock or one of its competitors? The main competitors of Cara Therapeutics include BeyondSpring (BYSI), Cellectar Biosciences (CLRB), AlloVir (ALVR), Aligos Therapeutics (ALGS), Celularity (CELU), ALX Oncology (ALXO), Immuneering (IMRX), Metagenomi (MGX), Spero Therapeutics (SPRO), and InterCure (INCR). These companies are all part of the "pharmaceutical products" industry. Cara Therapeutics vs. BeyondSpring Cellectar Biosciences AlloVir Aligos Therapeutics Celularity ALX Oncology Immuneering Metagenomi Spero Therapeutics InterCure Cara Therapeutics (NASDAQ:CARA) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, community ranking, profitability, earnings and analyst recommendations. Is CARA or BYSI more profitable? BeyondSpring has a net margin of 0.00% compared to Cara Therapeutics' net margin of -1,099.76%. BeyondSpring's return on equity of 0.00% beat Cara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cara Therapeutics-1,099.76% -367.97% -107.43% BeyondSpring N/A N/A N/A Does the media favor CARA or BYSI? In the previous week, Cara Therapeutics had 3 more articles in the media than BeyondSpring. MarketBeat recorded 3 mentions for Cara Therapeutics and 0 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 0.00 beat Cara Therapeutics' score of -0.18 indicating that BeyondSpring is being referred to more favorably in the news media. Company Overall Sentiment Cara Therapeutics Neutral BeyondSpring Neutral Which has more risk & volatility, CARA or BYSI? Cara Therapeutics has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, BeyondSpring has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. Does the MarketBeat Community prefer CARA or BYSI? Cara Therapeutics received 482 more outperform votes than BeyondSpring when rated by MarketBeat users. Likewise, 72.98% of users gave Cara Therapeutics an outperform vote while only 66.79% of users gave BeyondSpring an outperform vote. CompanyUnderperformOutperformCara TherapeuticsOutperform Votes66772.98% Underperform Votes24727.02% BeyondSpringOutperform Votes18566.79% Underperform Votes9233.21% Do analysts prefer CARA or BYSI? Cara Therapeutics currently has a consensus target price of $2.32, suggesting a potential upside of 660.66%. Given Cara Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Cara Therapeutics is more favorable than BeyondSpring.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cara Therapeutics 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00BeyondSpring 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders believe in CARA or BYSI? 44.7% of Cara Therapeutics shares are owned by institutional investors. Comparatively, 40.3% of BeyondSpring shares are owned by institutional investors. 3.1% of Cara Therapeutics shares are owned by insiders. Comparatively, 29.3% of BeyondSpring shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better earnings and valuation, CARA or BYSI? BeyondSpring has lower revenue, but higher earnings than Cara Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCara Therapeutics$20.97M0.80-$118.51M-$1.75-0.17BeyondSpring$1.75M38.14-$21.03MN/AN/A SummaryCara Therapeutics beats BeyondSpring on 8 of the 15 factors compared between the two stocks. Ad DTIWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! Get Cara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CARA vs. The Competition Export to ExcelMetricCara TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.73M$6.45B$5.04B$8.81BDividend YieldN/A8.11%5.16%4.07%P/E Ratio-0.1710.78130.5317.82Price / Sales0.80243.701,183.8674.55Price / CashN/A22.1633.6132.53Price / Book0.295.474.684.68Net Income-$118.51M$153.61M$119.23M$226.08M7 Day Performance-6.90%-2.00%-1.83%-1.04%1 Month Performance14.83%-7.46%-3.61%1.04%1 Year Performance-69.80%31.82%31.74%26.28% Cara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CARACara Therapeutics3.9339 of 5 stars$0.31flat$2.32+660.7%-71.2%$16.73M$20.97M-0.1755Analyst ForecastBYSIBeyondSpringN/A$1.71-0.6%N/A+86.1%$66.74M$1.75M0.0080CLRBCellectar Biosciences2.4949 of 5 stars$1.56-3.1%$20.00+1,182.1%-27.8%$66.44MN/A-0.9110Analyst ForecastShort Interest ↓Analyst RevisionNews CoverageALVRAlloVir2.6268 of 5 stars$0.57+1.8%N/A-65.2%$65.87MN/A-0.65110Positive NewsALGSAligos Therapeutics4.3215 of 5 stars$18.20-1.6%$75.00+312.1%+5.5%$65.30M$6.00M-1.3990High Trading VolumeCELUCelularity0.5369 of 5 stars$2.94+0.7%N/A+42.7%$64.19M$22.77M0.00220News CoverageALXOALX Oncology3.3343 of 5 stars$1.21-1.6%$12.50+933.1%-87.7%$63.82MN/A-0.4140IMRXImmuneering3.1656 of 5 stars$2.04flat$12.80+527.5%-63.4%$63.34M$320,000.000.0060Analyst ForecastMGXMetagenomi2.8114 of 5 stars$1.65-2.4%$15.50+839.4%N/A$63.25M$44.76M0.00236Analyst ForecastSPROSpero Therapeutics4.5933 of 5 stars$1.20+3.4%$5.00+316.7%-2.4%$63.24M$103.78M17.1546Analyst ForecastINCRInterCure1.2491 of 5 stars$1.33-3.6%N/A+16.0%$62.89M$96.61M0.00350Positive News Related Companies and Tools Related Companies BeyondSpring Competitors Cellectar Biosciences Competitors AlloVir Competitors Aligos Therapeutics Competitors Celularity Competitors ALX Oncology Competitors Immuneering Competitors Metagenomi Competitors Spero Therapeutics Competitors InterCure Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CARA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
